@article{2f3e73e250404adb99a6eb90b9a58550,
title = "Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia",
abstract = "Preliminary information has suggested that megestrol acetate leads to appetite stimulation and nonfluid weight gain in patients with breast cancer, other cancers, and AIDS. Pursuant to this, we developed a randomized, double-blind, placebo-controlled trial of megestrol acetate in patients with cancer-associated anorexia and cachexia. We randomly assigned 133 eligible patients to receive 800 mg of megestrol acetate per day or a placebo. Patients assigned to megestrol acetate more frequently reported improved appetite (P = .003) and food intake (P = .009) when compared with patients receiving the placebo. A weight gain of 15 Ib or more over baseline was seen in 11 of 67 (16%) patients receiving megestrol acetate compared with one of 66 (2%) given the placebo (P = .003). Patients receiving megestrol acetate reported significantly less nausea (13% vs. 38%; P = .001) and emesis (8% vs. 25%, P = .009). No clinically or statistically significant toxic reactions were ascribed to megestrol acetate, with the exception of mild edema. This study convincingly demonstrated that megestrol acetate can stimulate appetite and food intake in patients with anorexia and cachexia associated with cancer, leading to significant weight gain in a proportion of such patients.",
author = "Loprinzi, {Charles L.} and Ellison, {Neil M.} and Schaid, {Daniel J.} and Krook, {James E.} and Athmann, {Laureen M.} and Dose, {Ann Marie} and Mailliard, {James A.} and Johnson, {P. Steven} and Ebbert, {Larry P.} and Geeraerts, {Louis H.}",
note = "Funding Information: Received March 21, 1990; revised April 16, 1990; accepted April 17, 1990. Supported in part by Public Health Service grants CA-25224, CA-37404, CA-15083, CA-35269, CA-35101, CA-35103, CA-35113, CA-35272, CA-35448, and CA-37417 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services. This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and the Mayo Clinic. C. L. Loprinzi, A. M. Dose (Division of Medical Oncology), D. J. Schaid (Cancer Center Statistics Unit), Mayo Clinic, Rochester, Minn. N. M. Ellison, Geisinger Clinic and Medical Center Community Clinic Oncology Program (CCOP), Danville, Pa. J. E. Krook, L. M. Athmann, The Duluth Clinic CCOP, Duluth, Minn. J. A. Mailliard, P. S. Johnson, Creighton University, Omaha, Neb. L. P. Ebbert, Rapid City Regional Oncology Group, Rapid City, SD. L. H. Geeraerts, St. Luke's Hospitals CCOP, Fargo, ND. We thank Bristol-Myers Squibb for supplying megestrol acetate (Megace) and the placebo for this trial. Correspondence to: Charles L. Loprinzi, M.D., Mayo Clinic, 200 First St., S.W., Rochester, MN 55905.",
year = "1990",
month = jul,
day = "4",
doi = "10.1093/jnci/82.13.1127",
language = "English (US)",
volume = "82",
pages = "1127--1132",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "13",
}